Ten-year follow-up of lung cancer patients with resected adenocarcinoma in situ or minimally invasive adenocarcinoma: Wedge resection is curative

医学 楔形切除术 腺癌 肺癌 外科 内科学 癌症 切除术
作者
Di Li,Chaoqiang Deng,Shengping Wang,Yuan Li,Yang Zhang,Haiquan Chen
出处
期刊:The Journal of Thoracic and Cardiovascular Surgery [American Association for Thoracic Surgery]
卷期号:164 (6): 1614-1622.e1 被引量:16
标识
DOI:10.1016/j.jtcvs.2022.06.017
摘要

Objective This study aimed to reveal the long-term outcomes of patients with lung cancer with adenocarcinoma in situ or minimally invasive adenocarcinoma after resection, in the context of the different surgical resection types. Methods Patients with lung adenocarcinoma who underwent resection between December 2007 and December 2012 were reviewed. Patients with pathological adenocarcinoma in situ or minimally invasive adenocarcinoma were enrolled. Postoperative survival and risk of developing second primary lung cancer were analyzed. Results After reevaluating the histological findings of 1696 patients with lung adenocarcinoma, we enrolled 53 with adenocarcinoma in situ and 72 with minimally invasive adenocarcinoma for analyses. Of all 125 patients with adenocarcinoma in situ/minimally invasive adenocarcinoma, 86 (68.8%) were female, 114 (91.2%) were nonsmokers, and most of them (78, 62.4%) underwent wedge resection. The median follow-up period after surgery was 111 months. The 10-year recurrence-free survivals of adenocarcinoma in situ and minimally invasive adenocarcinoma were all 100%, and the 10-year overall survivals of adenocarcinoma in situ and minimally invasive adenocarcinoma were 98.1% and 97.2%, respectively. There was no difference in 10-year recurrence-free survival between patients who underwent lobectomy and wedge resection. EGFR mutations were detected in 63.1% (41/65) of patients who underwent mutational analysis. The risks of developing second primary lung cancer for adenocarcinoma in situ and minimally invasive adenocarcinoma 10 years after resection were 8.4% and 4.3% (P = .298), respectively, and were not correlated with EGFR mutation status (P = .525). Conclusions Pathological adenocarcinoma in situ and minimally invasive adenocarcinoma have no recurrence during 10-year follow-up after resection, regardless of surgical procedure types. Surgery is curative for these patients, and wedge resection is the preferred surgical procedure for nodules in the proper location.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
饱满一手发布了新的文献求助10
1秒前
2秒前
邓志天发布了新的文献求助10
2秒前
彳亍1117应助SCI的芷蝶采纳,获得20
2秒前
2秒前
Ashley完成签到,获得积分20
3秒前
大橙子完成签到,获得积分10
3秒前
3秒前
CodeCraft应助liangliu采纳,获得10
3秒前
研友_Z729Mn发布了新的文献求助10
4秒前
ding应助科研通管家采纳,获得10
4秒前
大模型应助科研通管家采纳,获得10
4秒前
寻道图强应助科研通管家采纳,获得30
4秒前
YzD应助科研通管家采纳,获得10
4秒前
4秒前
4秒前
Ava应助科研通管家采纳,获得10
4秒前
赘婿应助科研通管家采纳,获得20
4秒前
科研通AI2S应助科研通管家采纳,获得10
4秒前
4秒前
kyfbrahha完成签到 ,获得积分10
4秒前
张小南应助科研通管家采纳,获得10
4秒前
小蘑菇应助科研通管家采纳,获得10
5秒前
5秒前
寻道图强应助科研通管家采纳,获得30
5秒前
Akim应助科研通管家采纳,获得10
5秒前
5秒前
5秒前
完美世界应助科研通管家采纳,获得10
5秒前
传奇3应助科研通管家采纳,获得10
5秒前
彭于晏应助科研通管家采纳,获得20
5秒前
脑洞疼应助科研通管家采纳,获得10
5秒前
吴彦祖应助科研通管家采纳,获得10
5秒前
DuesKing完成签到,获得积分10
5秒前
麦迪应助科研通管家采纳,获得10
5秒前
5秒前
FashionBoy应助科研通管家采纳,获得10
5秒前
香蕉觅云应助科研通管家采纳,获得10
5秒前
搜集达人应助科研通管家采纳,获得10
5秒前
Akim应助未来的长江学者采纳,获得10
5秒前
高分求助中
Handbook of Fuel Cells, 6 Volume Set 1666
求助这个网站里的问题集 1000
Floxuridine; Third Edition 1000
Tracking and Data Fusion: A Handbook of Algorithms 1000
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 800
消化器内視鏡関連の偶発症に関する第7回全国調査報告2019〜2021年までの3年間 500
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 内科学 物理 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 冶金 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 2862358
求助须知:如何正确求助?哪些是违规求助? 2468242
关于积分的说明 6693068
捐赠科研通 2159043
什么是DOI,文献DOI怎么找? 1146996
版权声明 585178
科研通“疑难数据库(出版商)”最低求助积分说明 563543